SecBot SecBot
8-K ·Filed Aug 10, 2026

HIMS

Hims & Hers Health, Inc.
MIXED
Impact 7/10
Horizondays Processed2mo ago SEC0001773751-26-000161
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The massive revenue beat and raised top-line guidance are bullish, but the GAAP net loss, margin compression, and lowered EBITDA guidance create a mixed picture. Traders should watch the earnings call for clarity on GLP-1 margin trajectory, Eucalyptus integration costs, and the sustainability of domestic revenue acceleration before taking a directional position.

DirectionMixed
Confidencehigh
Horizondays
Latest settled — T+20d ⚠ clustered
HIMS ▼ -8.55% at T+20d
NEUTRAL call -8.55% · α vs SPY -7.50% · entry $30.51 → $27.90
Next anchor: T+60d in 8d
Latest observation: T+52 -14.38% FF3 residual α
Entry = T+0 close
Aug 10, 2026
via day close
T+1d
-1.77%
call -1.77% · α -2.02%
$29.97
settled 3mo ago
T+5d
-10.23%
call -10.23% · α -9.82%
$27.39
settled 2mo ago
T+20d
-8.55%
call -8.55% · α -7.50%
$27.90
settled 7w ago
T+60d
Pending
in 8d

Price Chart

Loading chart...

Executive Summary

Hims & Hers Health reported Q2 2026 revenue of $753.2M (+38% YoY), significantly beating the $730.1M consensus, driven by a 19% subscriber increase and 21% growth in monthly revenue per subscriber. However, GAAP net loss widened to $86.3M (EPS -$0.37) from a $42.5M profit a year ago, missing the -$0.05 consensus estimate due to acquisition costs, legal contingencies, and restructuring charges. The company raised full-year 2026 revenue guidance to $3.1B-$3.3B (from $2.8B-$3.0B) but lowered Adjusted EBITDA guidance to $275M-$325M (from $275M-$350M), signaling a trade-off between top-line acceleration and near-term margin compression from the Eucalyptus acquisition and GLP-1 strategic pivot.

Key Financial Metrics

EPS
−$0.37
est −$0.05 · -640.0%
Revenue
$753.2M
est $730.1M · +3.2% · +38.0% YoY
Rating
miss
Guidance
$3.1B-$3.3B
raised
Free Cash Flow
-$68.2M
Gross Margin
64%

Key Facts

  • Revenue of $753.2M (+38% YoY) beat $730.1M consensus.
  • GAAP net loss of $86.3M vs net income of $42.5M YoY; GAAP EPS -$0.37 missed consensus of -$0.05.
  • Full-year 2026 revenue guidance raised to $3.1B-$3.3B; Adjusted EBITDA guidance lowered to $275M-$325M.
  • Subscribers grew 19% YoY to 2.89M; monthly revenue per subscriber rose 21% YoY to $92.
  • Gross margin compressed to 64% from 76% YoY due to GLP-1 product mix shift and restructuring charges.
  • Eucalyptus acquisition closed in June, driving international revenue up 1,641% YoY to $131.4M.
  • Operating cash flow was -$35.9M in Q2; free cash flow was -$68.2M.
  • Legal contingencies of $47.5M and acquisition/restructuring costs weighed on GAAP profitability.

Financial Impact

Revenue beat consensus by $23.1M (+3.2%); GAAP EPS missed by -$0.32; full-year revenue guidance raised by $300M at midpoint; Adjusted EBITDA guidance lowered by $12.5M at midpoint.

revenueepsgross marginadjusted EBITDAoperating cash flowfree cash flow

Risk Factors

  • GAAP profitability remains negative with widening losses due to acquisition, restructuring, and legal costs.
  • Gross margin compression from GLP-1 product mix shift could persist, pressuring long-term unit economics.
  • Negative free cash flow and operating cash flow raise questions about cash burn sustainability post-acquisition.

Market Snapshot

Exchange
NYSE
Sector
Services-Offices & Clinics of Doctors of Medicine
Analyst Consensus
41% bullish (22 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001773751-26-000161
Document: hims-20260810.htm0001773751-26-000161
Document: 0001773751-26-000161-index-headers.html0001773751-26-000161
Document: 0001773751-26-000161-index.html0001773751-26-000161
Document: 0001773751-26-000161.txt0001773751-26-000161
8-K Data (Synthetic)0001773751-26-000161
18 reports for HIMS
Performance horizon
60% Hit rate @ T+20 3 of 5 directional calls Went positive at some point 4 of 5 best @ T+20▲ +36.57%Jun 2, 2026
Filters
Rows
Reports for HIMS — sortable, filterable
TypeNow
Oct 7, 2026
19d ago
8-K
NEUTRAL ★ 3/10
$28.06awaiting T+20—$27.59 (−1.67%)
Sep 23, 2026
4w ago
Insider Cluster
BEARISH ★ 5/10
$29.28 $29.13▲ +0.51%▲ +0.09%$27.59 (+5.77%)
Sep 18, 2026
5w ago
Insider Cluster
BEARISH ★ 4/10
$29.35 $28.15▲ +4.09%▲ +3.18%$27.59 (+6.00%)
Sep 17, 2026
5w ago
Insider Cluster
BEARISH ★ 4/10
$27.99 $28.07▼ −0.29%▼ −0.08%$27.59 (+1.43%)
Aug 20, 2026
9w ago
Insider Cluster
NEUTRAL ★ 3/10
$33.78 $29.35▼ −13.11%▼ −14.13%$27.59 (−18.32%)
Aug 20, 2026
9w ago
Insider Cluster
NEUTRAL ★ 3/10
$33.78 $29.35▼ −13.11%▼ −14.13%$27.59 (−18.32%)
Aug 18, 2026
9w ago
Insider Cluster
NEUTRAL ★ 3/10
$31.09 $27.89▼ −10.29%▼ −9.45%$27.59 (−11.26%)
Aug 10, 2026
11w ago
8-K
MIXED ★ 7/10
$30.51 $27.90▼ −8.55%▼ −7.50%$27.59 (−9.57%)
Jul 1, 2026
16w ago
8-K
NEUTRAL ★ 5/10
$36.80 $27.04▼ −26.52%▼ −26.11%$27.59 (−25.03%)
Jun 17, 2026
18w ago
Insider Cluster
NEUTRAL ★ 2/10
$35.47 $33.68▼ −5.05%▼ −5.58%$27.59 (−22.22%)
Showing 10 of 18

US Market Status

Market Closed — Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026